P:5/7 – Linezolid  by unknown
COndusion: Linezolid was 6-fold more active than vancomycin against
CNS and enterococci and 100fold more active than teicoplanin against CNS.
Linezolid was 2-fold more active than teicoplanin and vancomycin against
S. aureus. Linezolid is a promising drug to treat infections caused by Gram-
positive cocci.
thromycin (ERY), ampicillin (AMP) and other antibiotics against Gram-
positive micro-organisms. Strains were isolated fromJune 1999 untilJanuary
2000 from hospitalized and non-hospitalized (only for pneumococci)
patients with clinical significant infections. 1250 strains from blood.
sputum, pus and CSF were included. MICs were obtained with the Erest.
BHI agar and an inoculum of2.0 McFarland was used for staphylococci and
enterococci (glycopeptides only) to support a better growth and clear
recognition of hetero-resistant colonies. The NCCLS method was used
for all other testing. Results are expressed as below:
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extension plays a key role in the enhanced ribosomal binding of TEL, this
group on its own is unable to interact with the 23S rRNA. It is possible that
ketolides such as TEL dock into domain V ofthe rRNA target guiding the
Cll,l2-alkyl/aryl extension into a position where it can make contact with
domain II.
p:sn - Linezolid
IWeP991/n vitro activity of Iinezolid against staphylococd
C. Cuny, W. Witte
Robert Koch Institute, Wernigerode, Branch, 38855 Wernigerode, Germany
Objective: To determine MIC profiles oflinezolid for MSSA, MRSA and
coagulase negative staphylococci.
Design: MSSA (n = 245) and MRSA (n = 58) and coagulase negative
staphylococci (n = 197) of different origin sent from all over Germany to
the national staphylococcal reference center were subjected to genomic
typing (Smal macrorcstriction pattern) and to in "itro susceptibility testing
by means 'of microbroth MIC. Mutant frequencies were determined by
plating of aliquots from broth cultures onto isosensitest agar containing 8
mg/l linezolid.
Results: MIC's for linezolid were in the range between 0.5 and 2.0 mg/I. It
was not possible to select in vitro mutants among 10111 cfu, also not for MRSA
obviously possessing mutator alleles (elevated mutant frequencies for rifs-+
rifr, tmp-s -+ tmp-r).
Conclusion: MSSA and MRSA belonging to different clonal groups of S.
aureus are sensitive to linozolid. Mutation to resistance is obviously a rare
event.
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IWeP100IA Pan-European multicentre susceptibility study
(PEMSS) of clinical isolates to llnezolid and other comparator
antibiotics
C. G. Gemmell
On behalfofcontributors to PEMSS; University ofGlasgow, United Kingdom
Medical School, Bacteriology Department
A Pan-European Multicentre Susceptibility Study tested a total of 3382
recently isolated bacterial clinical isolates which were associated with skin,
blood or respiratory tract infection. Isolates originated from France, Italy,
Germany, Spain, The Netherlands, Sweden and the United Kingdom.
Laboratories in each country independently conducted in vitro susceptibility
tests using National Committee for Clinical Laboratory Standards
(NCCLS) broth microdilution and E-test agar dilution methodology.
MIC values for each organism were determined and MIC50 and MIC90
values were calculated. The activity of Iinezolid was compared to that of
appropriate comparator agents. Linezolid demonstrated excellent activity
against all of the Gram-positive bacteria tested including methicillin-
resistant staphylococci, vancomycin-resistant enterococci and penicillin-
resistant pneumococci. Linezolid demonstrated only modest activity against
the Gram-negative respiratory tract pathogens Moraxella catarrhalis and
Haemophilus injluenzae. When the MIC data for all countries were com-
bined, the MIC50 and MIC90 values were comparable. Overall, the lowest
MIC values were obtained for isolates from Italy and the highest values were
for isolates from The Netherlands. Correlation of broth microdilutioD and
E-test MIC values indicated very similar results for vancomycin except for
VRE. Both methods indicated resistance but the MICs varied by 4-fold.
There was also little variation between MIC values for penicillin and
amoxicillin/clavulanic acid using the two methods. Linezolid E-test results
were generally lower than those obtained by the broth microdilution assay.
Overall, Iinezolid was highly active against European isolates of Gram-
positive bacteria consistent with the results of other global studies.
IWeP1011 Multi-center in vitro evaluation of Iinezolid
compared with other antibiotics in The Netherlands
A. R.Janszl,j. W. Mouton2
lpAMM Laboratory for Medical Microbiology, Veldhoven; 2Canisius
Wilhelmina Hospital, Nijmegen, Netherlands
35 Laboratories participated in a multi-ccntre study in The Netherlands to
assess the in vitro activity oflinezolid (LIN), vancomycin (VAN), teicopla-
Din (TEl), oxacillin (OXA), penicillin G (pEN), gentamicin (GEN), ery-
IWeP1 021 Susceptibility of gram-positive cocci from 25 UK
hospitals to Iinezolid and other antibiotics
C. Henwood. D. Livermore, A.Johnson, D.James. M. Warner
Linezolid Study Group; ARMRL, Colindale, London, United Kingdom
Objectives: To determine the prevalence of antibiotic resistance amongst
gram-positive cocci isolated in UK hospitals.
Methods: 25 geographically diverse UK hospitals collected consecutive,
clinically significant isolates comprising: 30 Staphylococcus aureus, 30 coagu-
lase negative staphylococci (CNS), 40 enterococci and 40 Streptoco«Us
pneumotliae. Isolates were tested using E-tests according to NCCLS criteria.
For quality control, 10% ofisolates plus those with unusual resistances were
re-tested centrally.
Results: The overall resistance rates to methicillin in S. aureus and CNS
were 19.5% and 68.9% respectively. MRSA rates in individual hospitals
ranged from 0-43.3%. Vancomycin resistance in enterococci was signifi-
cantly higher in Eltterococcus faecium (24.1 %) than E. faecalis (0.5%) (p <
0.05) with resistant isolates carrying the vanA gene. The overall resistance
rate to penicillin amongst pneumococci was 8.9%. This resistance was
predominantly intermediate resistance; with only 6 hospitals reporting
high level penicillin resistance in pneumococci. No resistance to linezolid
was found in any ofthe organisms tested; MICs for staphylococci were 0.06-
4 mg/L; for enterococci 0.12-4 mg/L and for pneumococci 0.12-4 mg/L.
Conclusions: Resistance to established antimicrobials is common in gram-
positive cocci in UK hospitals. Linezolid may prove a useful therapeutic
alternative.
P:5/8 - Macrolides
/WeP1031 Macrolide resistance in StTeptococcus pneumonlae
in Russia
T. Bogdanovitcht, L. Stratchounskil• P. Huovinen2
lSmolensk Medical Academy Smolensk, Russian Federation; 2National Public
Health Institute, Turku, Finlaltd
Objectives: To investigate the incidence and mechanisms of macrolide
resistance in clinical isolates of S. pneumoltiae
Methods: 111 clinical strains ofS. pneumoniae isolated during the 1999 were
studied. The MICs of erythromycin, azithromycin, spiramycin and cIin-
damycin were determined by the NCCLS agar dilution technique. All
erythromycin-resistant (ER) strains were further evaluated by PCR for the
presence of prm and mefgenes.
